{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-047670","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.249400+00:00","generated_at":"2026-05-16T02:59:52.444068+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Karyopharm FY2025 total rev $146M; XPOVIO $115M; net loss $196M; FY2026 guidance $130-150M; key trial readouts in 2026","bullets":["FY2025 total revenue $146.1M (up from $145.2M); U.S. XPOVIO net product revenue $114.9M (up from $112.8M).","FY2025 net loss $196.0M ($17.93/share) vs $76.4M prior year, driven by $62.4M loss on debt extinguishment.","Cash, cash equivalents and investments $64.1M at Dec 31, 2025 vs $109.1M at Dec 31, 2024; runway into Q2 2026.","FY2026 guidance: total revenue $130-150M, XPOVIO net product $115-130M, R&D+SG&A $230-245M.","Phase 3 SENTRY myelofibrosis trial top-line data expected March 2026; Phase 3 endometrial cancer data mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-047670","json":"https://secwatch.observer/filing/0001193125-26-047670.json","markdown":"https://secwatch.observer/filing/0001193125-26-047670.md","text":"https://secwatch.observer/filing/0001193125-26-047670.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312526047670/0001193125-26-047670-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312526047670/kpti-20260212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:59:52.444068+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}